Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Fusion Antibodies Plc ( (GB:FAB) ) just unveiled an update.
Fusion Antibodies plc announced progress in its OptiMAL® validation project in collaboration with the National Cancer Institute (NCI). The project involves identifying antibody-expressing cells that bind to targeted interests using Fusion’s OptiMAL® Library. Fusion will extract and sequence DNA from these cells for further analysis, assisting in the validation of the OptiMAL® platform. This collaboration may enhance Fusion’s position in the market by advancing the discovery of novel antibodies, potentially benefiting stakeholders through improved cancer research and therapeutic development.
More about Fusion Antibodies Plc
Fusion Antibodies plc is a Belfast-based contract research organization specializing in antibody engineering services for therapeutic drug and diagnostic applications. Since its establishment in 2001 as a spin-out from Queen’s University Belfast, Fusion has developed a proprietary CDRx platform and has a global client base that includes top pharmaceutical companies. Its mission is to aid pharmaceutical and diagnostic companies in creating innovative products efficiently, leveraging the latest technology to accelerate drug development.
YTD Price Performance: 24.11%
Average Trading Volume: 1,507,663
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £8.64M
See more insights into FAB stock on TipRanks’ Stock Analysis page.
